Trial Profile
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Adenocarcinoma; Glucagonoma; Insulinoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 04 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 14 Nov 2023 Planned End Date changed from 1 Jul 2023 to 1 Jan 2024.
- 19 Oct 2022 Results assessing efficacy and safety of temozolomide versus temozolomide in combination with capecitabine in patients with advanced pancreatic neuroendocrine tumors, published in the Journal of Clinical Oncology.